207 related articles for article (PubMed ID: 34949655)
1. Extent and Instability of Trimethylation of Histone H3 Lysine Increases With Degree of Malignancy and Methionine Addiction.
Yamamoto J; Aoki Y; Inubushi S; Han Q; Hamada K; Tashiro Y; Miyake K; Matsuyama R; Bouvet M; Clarke SG; Endo I; Hoffman RM
Cancer Genomics Proteomics; 2022; 19(1):12-18. PubMed ID: 34949655
[TBL] [Abstract][Full Text] [Related]
2. Reversion of methionine addiction of osteosarcoma cells to methionine independence results in loss of malignancy, modulation of the epithelial-mesenchymal phenotype and alteration of histone-H3 lysine-methylation.
Aoki Y; Han Q; Tome Y; Yamamoto J; Kubota Y; Masaki N; Obara K; Hamada K; Wang JD; Inubushi S; Bouvet M; Clarke SG; Nishida K; Hoffman RM
Front Oncol; 2022; 12():1009548. PubMed ID: 36408173
[TBL] [Abstract][Full Text] [Related]
3. Histone H3 lysine-trimethylation markers are decreased by recombinant methioninase and increased by methotrexate at concentrations which inhibit methionine-addicted osteosarcoma cell proliferation.
Aoki Y; Tome Y; Han Q; Yamamoto J; Hamada K; Masaki N; Bouvet M; Nishida K; Hoffman RM
Biochem Biophys Rep; 2021 Dec; 28():101177. PubMed ID: 34877414
[TBL] [Abstract][Full Text] [Related]
4. Targeting altered cancer methionine metabolism with recombinant methioninase (rMETase) overcomes partial gemcitabine-resistance and regresses a patient-derived orthotopic xenograft (PDOX) nude mouse model of pancreatic cancer.
Kawaguchi K; Miyake K; Han Q; Li S; Tan Y; Igarashi K; Lwin TM; Higuchi T; Kiyuna T; Miyake M; Oshiro H; Bouvet M; Unno M; Hoffman RM
Cell Cycle; 2018; 17(7):868-873. PubMed ID: 29623758
[TBL] [Abstract][Full Text] [Related]
5. Histone methylation status of H3K4me3 and H3K9me3 under methionine restriction is unstable in methionine-addicted cancer cells, but stable in normal cells.
Yamamoto J; Han Q; Inubushi S; Sugisawa N; Hamada K; Nishino H; Miyake K; Kumamoto T; Matsuyama R; Bouvet M; Endo I; Hoffman RM
Biochem Biophys Res Commun; 2020 Dec; 533(4):1034-1038. PubMed ID: 33019978
[TBL] [Abstract][Full Text] [Related]
6. Triple-Methyl Blockade With Recombinant Methioninase, Cycloleucine, and Azacitidine Arrests a Pancreatic Cancer Patient-Derived Orthotopic Xenograft Model.
Sugisawa N; Yamamoto J; Han Q; Tan Y; Tashiro Y; Nishino H; Inubushi S; Hamada K; Kawaguchi K; Unno M; Bouvet M; Hoffman RM
Pancreas; 2021 Jan; 50(1):93-98. PubMed ID: 33370029
[TBL] [Abstract][Full Text] [Related]
7. Recombinant methioninase effectively targets a Ewing's sarcoma in a patient-derived orthotopic xenograft (PDOX) nude-mouse model.
Murakami T; Li S; Han Q; Tan Y; Kiyuna T; Igarashi K; Kawaguchi K; Hwang HK; Miyake K; Singh AS; Nelson SD; Dry SM; Li Y; Hiroshima Y; Lwin TM; DeLong JC; Chishima T; Tanaka K; Bouvet M; Endo I; Eilber FC; Hoffman RM
Oncotarget; 2017 May; 8(22):35630-35638. PubMed ID: 28404944
[TBL] [Abstract][Full Text] [Related]
8. Linkage of methionine addiction, histone lysine hypermethylation, and malignancy.
Yamamoto J; Inubushi S; Han Q; Tashiro Y; Sugisawa N; Hamada K; Aoki Y; Miyake K; Matsuyama R; Bouvet M; Clarke SG; Endo I; Hoffman RM
iScience; 2022 Apr; 25(4):104162. PubMed ID: 35434545
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of Recombinant Methioninase (rMETase) on Recalcitrant Cancer Patient-Derived Orthotopic Xenograft (PDOX) Mouse Models: A Review.
Kawaguchi K; Han Q; Li S; Tan Y; Igarashi K; Murakami T; Unno M; Hoffman RM
Cells; 2019 May; 8(5):. PubMed ID: 31052611
[TBL] [Abstract][Full Text] [Related]
10. Oral-recombinant Methioninase in Combination With Rapamycin Eradicates Osteosarcoma of the Breast in a Patient-derived Orthotopic Xenograft Mouse Model.
Masaki N; Han Q; Samonte C; Wu NF; Hozumi C; Wu J; Obara K; Kubota Y; Aoki Y; Bouvet M; Hoffman RM
Anticancer Res; 2022 Nov; 42(11):5217-5222. PubMed ID: 36288875
[TBL] [Abstract][Full Text] [Related]
11. Oral recombinant methioninase increases TRAIL receptor-2 expression to regress pancreatic cancer in combination with agonist tigatuzumab in an orthotopic mouse model.
Yamamoto J; Miyake K; Han Q; Tan Y; Inubushi S; Sugisawa N; Higuchi T; Tashiro Y; Nishino H; Homma Y; Matsuyama R; Chawla SP; Bouvet M; Singh SR; Endo I; Hoffman RM
Cancer Lett; 2020 Nov; 492():174-184. PubMed ID: 32739322
[TBL] [Abstract][Full Text] [Related]
12. Over-methylation of Histone H3 Lysines Is a Common Molecular Change Among the Three Major Types of Soft-tissue Sarcoma in Patient-derived Xenograft (PDX) Mouse Models.
Aoki Y; Yamamoto J; Tome Y; Hamada K; Masaki N; Inubushi S; Tashiro Y; Bouvet M; Endo I; Nishida K; Hoffman RM
Cancer Genomics Proteomics; 2021; 18(6):715-721. PubMed ID: 34697064
[TBL] [Abstract][Full Text] [Related]
13. Oncogenes and Methionine Addiction of Cancer: Role of
Aoki Y; Han Q; Kubota Y; Masaki N; Obara K; Tome Y; Bouvet M; Nishida K; Hoffman RM
Cancer Genomics Proteomics; 2023; 20(2):165-170. PubMed ID: 36870694
[TBL] [Abstract][Full Text] [Related]
14. Reversion from Methionine Addiction to Methionine Independence Results in Loss of Tumorigenic Potential of Highly-malignant Lung-cancer Cells.
Yamamoto J; Aoki Y; Han Q; Sugisawa N; Sun YU; Hamada K; Nishino H; Inubushi S; Miyake K; Matsuyama R; Bouvet M; Endo I; Hoffman RM
Anticancer Res; 2021 Feb; 41(2):641-643. PubMed ID: 33517268
[TBL] [Abstract][Full Text] [Related]
15. Recombinant Methioninase as a DNA Demethylation Agent.
Hoffman RM; Machover D
Methods Mol Biol; 2019; 1866():279-284. PubMed ID: 30725424
[TBL] [Abstract][Full Text] [Related]
16. Oral Installation of Recombinant Methioninase-producing
Kubota Y; Han Q; Hamada K; Aoki Y; Masaki N; Obara K; Baranov A; Bouvet M; Tsunoda T; Hoffman RM
Cancer Genomics Proteomics; 2022; 19(6):683-691. PubMed ID: 36316039
[TBL] [Abstract][Full Text] [Related]
17. Probe the function of histone lysine 36 methylation using histone H3 lysine 36 to methionine mutant transgene in mammalian cells.
Fang D; Gan H; Wang H; Zhou H; Zhang Z
Cell Cycle; 2017 Oct; 16(19):1781-1789. PubMed ID: 28129023
[TBL] [Abstract][Full Text] [Related]
18. Targeting methionine with oral recombinant methioninase (o-rMETase) arrests a patient-derived orthotopic xenograft (PDOX) model of BRAF-V600E mutant melanoma: implications for chronic clinical cancer therapy and prevention.
Kawaguchi K; Han Q; Li S; Tan Y; Igarashi K; Kiyuna T; Miyake K; Miyake M; Chmielowski B; Nelson SD; Russell TA; Dry SM; Li Y; Singh AS; Eckardt MA; Unno M; Eilber FC; Hoffman RM
Cell Cycle; 2018; 17(3):356-361. PubMed ID: 29187018
[TBL] [Abstract][Full Text] [Related]
19. High Efficacy of Recombinant Methioninase on Patient-Derived Orthotopic Xenograft (PDOX) Mouse Models of Cancer.
Hoffman RM; Murakami T; Kawaguchi K; Igarashi K; Tan Y; Li S; Han Q
Methods Mol Biol; 2019; 1866():149-161. PubMed ID: 30725414
[TBL] [Abstract][Full Text] [Related]
20. Oral-recombinant Methioninase Converts an Osteosarcoma from Methotrexate-resistant to -sensitive in a Patient-derived Orthotopic-xenograft (PDOX) Mouse Model.
Aoki Y; Tome Y; Han Q; Yamamoto J; Hamada K; Masaki N; Kubota Y; Bouvet M; Nishida K; Hoffman RM
Anticancer Res; 2022 Feb; 42(2):731-737. PubMed ID: 35093871
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
